LT2419104T - 5-ht4 receptoriaus agonistų ir acetilcholinesterazės inhibitorių deriniai, skirti pažinimo sutrikimų gydymui - Google Patents

5-ht4 receptoriaus agonistų ir acetilcholinesterazės inhibitorių deriniai, skirti pažinimo sutrikimų gydymui

Info

Publication number
LT2419104T
LT2419104T LTEP10713790.3T LT10713790T LT2419104T LT 2419104 T LT2419104 T LT 2419104T LT 10713790 T LT10713790 T LT 10713790T LT 2419104 T LT2419104 T LT 2419104T
Authority
LT
Lithuania
Prior art keywords
combinations
treatment
receptor agonists
cognitive disorders
acetylcholinesterase inhibitors
Prior art date
Application number
LTEP10713790.3T
Other languages
English (en)
Inventor
David Beattie
Fei Shen
Jacqueline A. M. Smith
Robert Murray Mckinnell
Ray Chang
Original Assignee
Theravance Biopharma R&D Ip, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Biopharma R&D Ip, Llc filed Critical Theravance Biopharma R&D Ip, Llc
Publication of LT2419104T publication Critical patent/LT2419104T/lt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/468-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy
LTEP10713790.3T 2009-04-13 2010-04-12 5-ht4 receptoriaus agonistų ir acetilcholinesterazės inhibitorių deriniai, skirti pažinimo sutrikimų gydymui LT2419104T (lt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16874109P 2009-04-13 2009-04-13
US29255910P 2010-01-06 2010-01-06
PCT/US2010/030760 WO2010120695A2 (en) 2009-04-13 2010-04-12 5-ht4 receptor agonist compounds for treatment of cognitive disorders

Publications (1)

Publication Number Publication Date
LT2419104T true LT2419104T (lt) 2018-02-12

Family

ID=42237213

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP10713790.3T LT2419104T (lt) 2009-04-13 2010-04-12 5-ht4 receptoriaus agonistų ir acetilcholinesterazės inhibitorių deriniai, skirti pažinimo sutrikimų gydymui

Country Status (23)

Country Link
US (2) US8404711B2 (lt)
EP (1) EP2419104B1 (lt)
JP (1) JP2012523437A (lt)
KR (1) KR20120017421A (lt)
CN (2) CN102395371A (lt)
AU (1) AU2010236734B2 (lt)
BR (1) BRPI1013777A8 (lt)
CA (1) CA2758321A1 (lt)
CY (1) CY1119800T1 (lt)
DK (1) DK2419104T3 (lt)
ES (1) ES2654930T3 (lt)
HR (1) HRP20180018T1 (lt)
HU (1) HUE038141T2 (lt)
IL (1) IL215660A0 (lt)
LT (1) LT2419104T (lt)
MX (1) MX2011010782A (lt)
NO (1) NO2419104T3 (lt)
PL (1) PL2419104T3 (lt)
PT (1) PT2419104T (lt)
RU (1) RU2569056C2 (lt)
SI (1) SI2419104T1 (lt)
WO (1) WO2010120695A2 (lt)
ZA (1) ZA201107490B (lt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
PL2889033T3 (pl) 2008-11-19 2018-10-31 Forum Pharmaceuticals Inc. Leczenie negatywnych objawów schizofrenii za pomocą (R)-7-chloro-N-(chinuklidyn-3-ylo)benzo[b]tiofeno-2-karboksyamidu i jego farmaceutycznie dopuszczalnych soli
WO2010132423A1 (en) * 2009-05-11 2010-11-18 Envivo Pharmaceuticals, Inc. Treatment of cognitive disorders with certain alpha-7 nicotinic acid receptors in combination with acetylcholinesterase inhibitors
MX2012013345A (es) 2010-05-17 2013-02-11 Envivo Pharmaceuticals Inc Una forma cristalina de clorhidrato de (r)-7-cloro-n-(quinuclidin- 3-il)benzo[b]tiofeno-2-carboxamida monohidratado.
CA2872005A1 (en) 2012-05-08 2013-11-14 Forum Pharmaceuticals, Inc. Methods of maintaining, treating or improving cognitive function
CN104781390B (zh) 2012-08-16 2017-07-28 庆熙大学校产学协力团 具有对衰老及痴呆的预防和/或治疗活性的乳酸菌
US10874701B2 (en) 2012-08-16 2020-12-29 University-Industry Cooperation Group Of Kyung Hee University Lactic acid bacteria capable of preventing and/or treating senescence and dementia
PT3630098T (pt) 2017-05-24 2021-04-21 H Lundbeck As Combinação de um antagonista do receptor 5-ht6 e de um inibidor de acetilcolinesterase para utilização no tratamento da doença de alzheimer numa subpopulação de pacientes portadores de alelos apoe4
EP3630113A4 (en) 2017-06-01 2021-02-24 Eisai R&D Management Co., Ltd. PHARMACEUTICAL COMPOSITION, INCLUDING PDE9 INHIBITOR
EP3632431A4 (en) 2017-06-02 2020-06-03 FUJIFILM Toyama Chemical Co., Ltd. AGENTS FOR PREVENTING OR TREATING BRAIN ATROPHY
MX2020001217A (es) 2017-07-31 2020-03-24 Theravance Biopharma R&D Ip Llc Metodos de tratamiento de sintomas de gastroparesia usando velusetrag.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE345803T1 (de) * 2000-03-03 2006-12-15 Eisai Co Ltd Neue methoden unter verwendung von cholinesteraseinhibitoren
TWI351282B (en) * 2004-04-07 2011-11-01 Theravance Inc Quinolinone-carboxamide compounds as 5-ht4 recepto
US7598265B2 (en) 2004-09-30 2009-10-06 Epix Delaware, Inc. Compositions and methods for treating CNS disorders
TWI377206B (en) * 2005-04-06 2012-11-21 Theravance Inc Crystalline form of a quinolinone-carboxamide compound
MY147756A (en) * 2005-05-25 2013-01-15 Theravance Inc Benzimidazole-carboxamide compounds as 5-ht4 receptor agonists

Also Published As

Publication number Publication date
US8404711B2 (en) 2013-03-26
NO2419104T3 (lt) 2018-04-07
PT2419104T (pt) 2018-01-31
SI2419104T1 (en) 2018-03-30
BRPI1013777A8 (pt) 2017-09-19
HUE038141T2 (hu) 2018-10-29
US20140057939A1 (en) 2014-02-27
CN105832735A (zh) 2016-08-10
CN102395371A (zh) 2012-03-28
US20100261752A1 (en) 2010-10-14
CY1119800T1 (el) 2018-06-27
WO2010120695A3 (en) 2010-12-02
ZA201107490B (en) 2012-06-27
MX2011010782A (es) 2012-01-20
JP2012523437A (ja) 2012-10-04
KR20120017421A (ko) 2012-02-28
CA2758321A1 (en) 2010-10-21
DK2419104T3 (en) 2018-02-05
EP2419104A2 (en) 2012-02-22
PL2419104T3 (pl) 2018-04-30
AU2010236734A1 (en) 2011-11-03
ES2654930T3 (es) 2018-02-15
IL215660A0 (en) 2012-01-31
RU2569056C2 (ru) 2015-11-20
BRPI1013777A2 (pt) 2016-04-05
HRP20180018T1 (hr) 2018-02-09
EP2419104B1 (en) 2017-11-08
WO2010120695A2 (en) 2010-10-21
RU2011146032A (ru) 2013-05-20
AU2010236734A8 (en) 2012-02-16
AU2010236734B2 (en) 2015-06-11

Similar Documents

Publication Publication Date Title
PL2419104T3 (pl) Kombinacje agonistów receptora 5-HT4 i inhibitorów acetylocholinoesterazy do leczenia zaburzeń poznawczych
PT2467372T (pt) Tratamento de distúrbios relacionados com bdnf usando laquinimod
EP2293800A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF EARLIER DISEASES
IL216140A0 (en) Egfr inhibitors and methods of treating disorders
EP2379559A4 (en) PYRIMIDO DIAZEPINONE KINASE FERTILIZERS AND METHOD FOR THE TREATMENT OF ILLNESSES
HK1199058A1 (en) Use of toll-like receptor and agonist for treating cancer toll-
ZA201001193B (en) 2-anilinopurin-8-ones as inhibitors of TTK/MPS1 for the treatment of proliferative disorders
EP2411001A4 (en) P2X3 RECEPTOR ANTAGONISTS FOR PAIN TREATMENT
EP2456868A4 (en) METHOD AND COMPOSITIONS FOR TREATING SUFFERING OF SUFFERING THROUGH MUSCARIN RECEPTOR ACTIVATION
EP2410858A4 (en) P2X3 RECEPTOR ANTAGONISTS FOR PAIN TREATMENT
EP2410857A4 (en) ANTAGONISTS OF THE P2X3 RECEPTOR FOR THE TREATMENT OF PAIN
HK1169804A1 (zh) 治療疼痛的方法
IL216281A0 (en) Treatment of cognitive disorders with certain alpha-7 nicotinic acid receptors in combination with acetylcholinesterase inhibitors
EP2488025A4 (en) SEPIAPTERIC INTREDUCTASE INHIBITION FOR PAIN TREATMENT
EP2640395A4 (en) TREATMENT OF DISEASES ASSOCIATED WITH SEARCH AND PULSE CONTROL BY PDE7 INHIBITORS
EP2509596A4 (en) COMPOUNDS AND METHOD FOR THE TREATMENT OF EYE DISEASES
HK1254745A1 (zh) Gpr119受體調節劑和對與其相關的障礙的治療
IL214455A0 (en) Methods and compositions for treatment of neovascularization
EP2393787A4 (en) CADHERINE 11 INHIBITORS AND METHOD FOR THEIR USE
ZA201106076B (en) Treatment of insulin-resistant disorders
EP2475390A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF TYROSINE KINASE RECEPTOR MEDIATION DISEASES OR DISORDERS
EP2424885A4 (en) COMPOSITIONS AND METHODS OF TREATING DISEASES RELATED TO EPITHELIAL CELL APOPTOSIS
EP2533780A4 (en) 5-HT4 RECEPTOR AGONISTS FOR THE TREATMENT OF DEMENTIA
ZA201202379B (en) Antagonists of dsgs2 for treatment of cancer
BR112013001939A2 (pt) tratamento de distúrbios cognitivos com determinados agonistas receptores de ácido alfa-7-nicotínico em combinação com inibidres de acetilcolinesterase